WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Dowload the full press release here.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3013
[post_author] => 3
[post_date] => 2018-12-15 20:15:57
[post_date_gmt] => 2018-12-15 20:15:57
[post_content] => As a BARDA DRIVe Accelerator, the Center for Biotechnology is pleased to announce that the simplified funding application process, called EZ BAA, is now open. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to submit abstracts beginning today using this simplified EZ BAA process.
Applications accepted through this streamlined process must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business friendly simple abstract.
In-scope priority areas include products and solutions to reduce illness and death from sepsis as part of DRIVe’s Solving Sepsis initiative; technologies and processes to identify infections and exposures to biological and other health threats, as outlined in the Early Notification to Act, Control, and Treat (ENACT) initiative; and tools and techniques to mitigate the damages and loss of life associated with catastrophic events.
Applying is simple:
- Download the application form the DRIVe website.
- Submit a technical abstract no longer than a 2,000 words
- Include a cost proposal of an additional 2,000 words or less.
- Proposed costs should not exceed $749,000.
What happens next:
- Once submitted, DRIVe’s experts will review the application to ensure it is within scope and meets DRIVe criteria.
- As the applicant, you’ll be notified of the review results within 30 days of your submission.
**The Center for Biotechnology is interested in working with potential applicants to help ensure the submission of a robust on-target proposal. If you are interested learning about how the Center for Biotechnology can help, please contact William Hanes: william.hanes@stonybrook.edu***
Learn more about the DRIVe EZ-BAA
review criteria here.
Have questions? Looking more information? Contact DRIVeContracting@hhs.gov
[post_title] => Funding Opportunity: BARDA DRIVe EZ-BAA
[post_excerpt] => Applications must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business friendly simple abstract.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => funding-opportunity-barda-drive-ez-baa
[to_ping] =>
[pinged] =>
[post_modified] => 2019-01-09 15:56:21
[post_modified_gmt] => 2019-01-09 15:56:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3013
[menu_order] => 108
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3462
[post_author] => 3
[post_date] => 2020-03-18 11:02:50
[post_date_gmt] => 2020-03-18 11:02:50
[post_content] => BARDA is calling for biomedical innovations to tackle COVID-19 pandemic through two major solilications. EZ-BAA solicitations for funding up to $750K, and BAA (no funding limit).
Deadline for EZ-BAA submission is June 30th. Innovations are sought for multiple areas (.e. molecular assays, point-of-care diagnostics, vaccines, therapeutics, manufacturing platform, devices, ventilators.) Innovators are encouraged to review the most updated proposal solicitations through the links below:
EZ BAA:
https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view
BARDA BAA:
https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view
Innovators are also welcome to submit quick applications to this market research portal on COVID-19 which are frequently reviewed by an inter-agency task force committee, including CDC, HHS, and NIH:
https://www.medicalcountermeasures.gov/app/barda/coronavirus.aspx
If you have any questions regarding your technology and how to engage with BARDA, Please contact Phuong Nguyen at the Center for Biotechnology for help:
phuong.t.nguyen@stonybrook.edu
[post_title] => BARDA: Call for innovations to tackle COVID-19
[post_excerpt] => BARDA is calling for biomedical innovations to tackle COVID-19 pandemic through two major solilications. EZ-BAA solicitations for funding up to $750K, and BAA (no funding limit).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => barda-call-for-innovations-to-tackle-covid-19
[to_ping] =>
[pinged] =>
[post_modified] => 2020-03-18 11:02:50
[post_modified_gmt] => 2020-03-18 11:02:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3462
[menu_order] => 73
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 1455
[post_author] => 3
[post_date] => 2015-03-16 19:45:43
[post_date_gmt] => 2015-03-16 19:45:43
[post_content] => Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, announced today that it has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY) for access to the animal health applications of a proprietary library of polyenolic zinc-binding agents. The license agreement also extends Traverse Biosciences the exclusive option to license the human health applications of these promising drug candidates.
The drug compounds were invented by Lorne Golub, DMD, MD (Honorary), Distinguished Professor in the Department of Oral Biology and Pathology in the Stony Brook University School of Dental Medicine, and Francis Johnson, PhD, President of Chem-Master International Inc. and Professor of Chemistry and Pharmacology at Stony Brook. The drugs were developed in concert with the the Center for Biotechnology at Stony Brook University. The Center provided financial support to help the inventors develop their lead compound and for follow-on animal studies.
Click to read the press releases from
Stony Brook University and
Traverse Biosciences.
[post_title] => Traverse Biosciences Executes Exclusive, Worldwide License Agreement
[post_excerpt] => Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => traverse-biosciences-executes-exclusive-worldwide-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2015-03-16 19:46:46
[post_modified_gmt] => 2015-03-16 19:46:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1455
[menu_order] => 209
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
Dowload the full press release here.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 282
[max_num_pages] => 94
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
